Standardisation in clinical laboratory medicine: An ethical reflection

Annals of the Rheumatic Diseases

Volumn 67, Issue 8, 2008, Pages 1061-1063

  Bossuyt, Xavier ^a   Louche, Céline ^b   Wiik, Allan ^c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b VLERICK BUSINESS SCHOOL   (Belgium)

^c STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL LABORATORY; CLINICAL MEDICINE; CONSUMER; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; EDITORIAL; GOVERNMENT; IN VITRO STUDY; MEDICAL ETHICS; ORGANIZATION; PRIORITY JOURNAL; SAFETY; SOCIAL BEHAVIOR; STANDARDIZATION;

CLINICAL MEDICINE; ETHICS, CLINICAL; HUMANS; LABORATORIES; PUBLIC POLICY; REAGENT KITS, DIAGNOSTIC; REFERENCE STANDARDS;

EID: 47949088293     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.084228     Document Type: Editorial

References (27)

1. Whicher JT, Ritchie RF, Johnson AM, Baudner S, Bienvenu J, Blirup-Jensen S, et al. New international reference preparation for proteins in human serum (RPPHS). Clin Chem 1994;40:934-8.
2. Johnson AM, Whicher JT. Effect of certified reference material 470 (CRM 470) on national quality assurance programs for serum proteins in Europe. Clin Chem Lab Med 2001;39:1123-8.
3. Feltkamp TE. Standards for ANA and anti-DNA. Clin Rheumatol 1990;9(Suppl 1):74-8.
4. Tan EM. International cooperative activities in standardization of antinuclear antibodies. In: Van Venrooij WJ, Maini RN, eds. Manual of biological markers of disease. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1993:A1-1-5.
5. Bossuyt X, Marien G, Meyts I, Proesmans M, De Boeck K. Determination of IgG subclasses: a need for standardization. J Allergy Clin Immunol 2005;115:872-4.
6. Vermeire S, Joossens S, Peeters M, Monsuur F, Marien G, Bossuyt X, et al. Comparative study of ASCA (anti-saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 2001;120:827-33.
7. Van Meensel B, Hiele M, Hoffman I, Vermeire S, Rutgeerts P, Geboes K, et al. Diagnostic accuracy of ten second-generation (human) tissue transglutaminase antibody assays in celiac disease. Clin Chem 2004;50:2125-35.
8. Coenen D, Verschueren P, Westhovens R, Bossuyt X. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007;53:498-504.
9. Committee of Autoantibody Standardization International Union of Immunological Societies. http://www.autoab.org (accessed 1 May 2007).
10. Ogburn WF. Cultural lag as theory. In William F Ogburn on culture and social change. Chicago, Illinois, USA: Phoenix books/The University of Chicago Press, 1964:86-95.
11. Kracher B, Corritore CL. Is there a special e-commerce ethics? Business Ethics Quarterly 2004;14:71-94.
12. Marshall KP. Has technology introduced new ethical problems? J Business Ethics 1999;19:81-90.
13. Wiik A, Gordon TP, Kavanaugh AF, Lahita RG, Reeves W, van Venrooij WJ, et al. Cutting edge diagnostics in rheumatology: the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. Arthritis Care Res 2004;51:291-8
14. Carroll B, Buchholtz AK. Business & society. ethics and stakeholder management. 6th edn. Belmont, California, USA: Thomson South Western, 2006.
15. World Health Organization. http://www.who.int/bloodproducts/ ref_materials/ert/ (accessed 1 May 2007).
16. Velasquez MG. Business ethics: concepts and cases. 4th edn. Upper Saddle River, New Jersey, USA: Prentice Hall, 1998:335-44.
17. Fritzler MJ, Wiik A, Fritzler ML, Barr SG. The use and abuse of commercial kits used to detect autoantibodies. Arthritis Res Ther 2003:192-201.
18. Tan EM, Smolen JS, McDougal JS, Butcher BT, Conn R, et al. A critical evaluation of enzyme immuno-assays for detection of antinuclear antibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum 1999;42:455-64.
19. Fritzler MJ, Wiik A, Tan EM, Smolen JS, McDougal JS, Chan EK, et al. A critical evaluation of enzyme immuno-assays for detection of antinuclear antibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturer's laboratories. J Rheumatol 2003;30:2374-81.
20. Smolen JS, Butcher B, Fritzler MJ, Gordon T, Hardin J, Kalden JR, et al. Reference sera for antinuclear antibodies. 2. Further definition of antibody specificities in international antinuclear antibody reference sera by immunfluorescence and Western blotting. Arthritis Rheum 1999;40:413-18.
21. Fenger M, Wiik A, Høier-Madsen M, Lykkegaard JJ, Rozenfeld T, Hansen MS, et al. Detection of antinuclear antibodies by solid-phase immunoassays and immunofluorescence analysis. Clin Chem 2004;50:2141-7.
22. Pottel H, Wiik A, Locht H, Gordon T, Roberts-Thomson P, Abraham D, et al. Clinical optimization and multicenter validation of antigen-specific cut-off values on the INIMOLIA ANA Update for the detection of autoantibodies in connective tissue disorders. Clin Exp Rheumatol 2004;22:579-88.
23. Leisinger KM. The corporate social responsibility of the pharmaceutical industry: idealism without illusion and realism without resignation. Business Ethics Quarterly 2005;15:577-94.
24. Code of ethics. European Diagnostic Manufacturers Association. http://www.edma-ivd.be (accessed 1 June 2007).
25. Hartning T, Harmeling S, Ventkataraman S. Innovative stakeholder relations: when "ethics pays" (and when it doesn't). Business Ethics Quarterly 2006;16:43-68.
26. Economic benefits of standardization. Summary of results, published by DIN German Institute for Standardization. http://www2.din.de/index. php?lang=en (accessed 1 May 2007).
27. Wiik A, Cervera R, Haass M, Khamashta M, Meroni PL, Piette J-C, et al. European attempts to set guidelines for diagnostics of autoimmune rheumatic disorders. Lupus 2006;15:391-6.